Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01587313 · ClinicalTrials.gov registry record · Phase 1
A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers
A Phase 1 study, sponsored by Arbor Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01587313 is a Phase 1 study that has completed, run by Arbor Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT01587313, a Phase 1 study, has completed, sponsored by Arbor Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a single center, open-label, two-period study. There will be nine healthy human volunteers arbitrarily assigned to one of four groups. The study objective is to compare the action of various combinations of BiDil extended-release capsules and commercial BiDil Tablets in the body over a period of time.
Interventions
- DRUG Isosorbide dinitrate / hydralazine capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01587313
The ClinicalTrials.gov registry entry for NCT01587313 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arbor Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Isosorbide dinitrate / hydralazine capsules is the first listed.
NCT01587313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01587313 about?
NCT01587313 is a clinical study titled "A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers". This is a single center, open-label, two-period study. There will be nine healthy human volunteers arbitrarily assigned to one of four groups. The study objective is to compare the action of various combinations of BiDil extended-release capsules and commercial BiDil Tablets in the body over a perio...
What is the current status of trial NCT01587313?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2012-04. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01587313?
The interventions under investigation include: Isosorbide dinitrate / hydralazine capsules (DRUG).
Who is sponsoring clinical trial NCT01587313?
This trial is sponsored by Arbor Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.